共 98 条
[1]
Brown DM(2006)Ranibizumab versus verteporfin for neovascular age-related macular degeneration N Engl J Med 355 1432-1444
[2]
Kaiser PK(2006)Ranibizumab for neovascular age-related macular degeneration N Engl J Med 355 1419-1431
[3]
Michels M(2011)Ranibizumab and bevacizumab for neovascular age-related macular degeneration N Engl J Med 364 1897-1908
[4]
Soubrane G(2015)Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol Ophthalmology 122 146-152
[5]
Heier JS(2019)Better visual outcome at 1 year with antivascular endothelial growth factor treatment according to treat-and-extend compared with pro re nata in eyes with neovascular age-related macular degeneration Acta Ophthalmol 97 519-524
[6]
Kim RY(2015)Defining response to anti-VEGF therapies in neovascular AMD Eye 29 721-731
[7]
Sy JP(2017)Intravitreal aflibercept in neovascular age-related macular degeneration with limited response to ranibizumab: a treat-and-extend trial Retina 3 1185-1192
[8]
Schneider S(2018)Switching anti-vascular endothelial growth factors in refractory neovascular age-related macular degeneration Ophthalmic Surg Lasers Imag Retina 49 166-170
[9]
Rosenfeld PJ(2019)Tachyphylaxis during treatment of exudative age-related macular degeneration with aflibercept Graefes Arch Clin Exp Ophthalmol 257 2559-2569
[10]
Brown DM(2015)Pigment epithelial detachment followed by retinal cystoid degeneration leads to vision loss in treatment of neovascular age-related macular degeneration Ophthalmology 122 822-832